Cited by 2,833Heart Failure Treatment and ManagementHeart rate and cardiovascular healthCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Open access

Cohn, Jay N., Johnson, Gary, Ziesche, Susan, Cobb, Frederick, Francis, Gary, Tristani, Felix, Smith, Raphael, Dunkman, W. Bruce, Loeb, Henry, Wong, Maylene, Bhat, Geetha, Goldman, Steven, Fletcher, Ross D., Doherty, James, Hughes, C. Vincent, Carson, Peter, Cintron, Guillermo, Shabetai, Ralph, Haakenson, Clair·1991·New England Journal of Medicine

DOI 10.1056/nejm199108013250502

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. RESULTS: Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (New York Heart Association class I or II). In contrast, body oxygen consumption at peak exercise was increased only by hydralazine-isosorbide dinitrate treatment (P less than 0.05), and left ventricular ejection fraction, which increased with both regimens during the 2 years after randomization, increased more (P less than 0.05) during the first 13 weeks in the hydralazine-isosorbide dinitrate group. CONCLUSIONS: The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199108013250502

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citation
A placebo-controlled trial of captopril in refractory chronic congestive heart failure
Captopril Multicenter Research Group (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80316-7 · Cited by 588
Vasodilator Therapy of Cardiac Failure
Cohn, J. N., & Franciosa, J. A. (1977) · New England Journal of Medicine · doi:10.1056/nejm197707072970105 · Cited by 483
Self-citation
The role of vasodilator therapy in heart failure
Chatterjee, K., & Parmley, W. W. (1977) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(77)90006-8 · Cited by 315
Vasodilator Therapy for Heart Failure
Cohn, J. N. (1973) · Circulation · doi:10.1161/01.cir.48.1.5 · Cited by 293
Self-citation
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.
Leier, C. V., Huss, P., Magorien, R. D., & Unverferth, D. V. (1983) · Circulation · doi:10.1161/01.cir.67.4.817 · Cited by 289

Show all 19 references

Research works printed but not linked: 1

Cohn, 1987, Circulation, 76, IV–443

Sorted by citations

Items 801–900 of 1,000

Heart Failure Disease Management: Impact on Hospital Care, Length of Stay, and Reimbursement
Discher, C. L., Klein, D., Pierce, L., Levine, A. B., & Levine, T. B. (2003) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2003.01461.x · Cited by 35
Race, Ethnicity, Ancestry, and Pharmacogenetics
Urban, T. J. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20168 · Cited by 35
Use of Isosorbide Dinitrate and Hydralazine in African-Americans With Heart Failure 9 Years After the African-American Heart Failure Trial
Ferdinand, K. C., Elkayam, U., MANCINI, D. M., Ofili, E., Piña, I. L., Anand, I. S., Feldman, A. M., McNamara, D. M., & Leggett, C. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.04.018 · Cited by 36
The Bi-directional Impact of Two Chronic Illnesses: Heart Failure and Diabetes – A review of the Epidemiology and Outcomes
Campbell, P. T., Krim, S. R., & Ventura, H. O. (2015) · Cardiac failure review · doi:10.15420/cfr.2015.01.01.8 · Cited by 35
Emerging role of pharmacogenomics in heart failure
McNamara, D. M. (2008) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3282fcd662 · Cited by 35
Load-induced changes in repolarization: evidence from experimental and clinical data
Eckardt, L., Kirchhof, P. F., Breithardt, G., & Haverkamp, W. (2001) · Basic Research in Cardiology · doi:10.1007/s003950170045 · Cited by 35
Myocardial Contractile Efficiency and Oxygen Cost of Contractility Are Preserved During Transition From Compensated Hypertrophy to Failure in Rats With Salt-Sensitive Hypertension
Morii, I., Kihara, Y., Inoko, M., & Sasayama, S. (1998) · Hypertension · doi:10.1161/01.hyp.31.4.949 · Cited by 35
Approach to symptomatic coronary disease in the elderly: TIME to change
Aronow, W. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06111-6 · Cited by 35
Heart Failure Therapy in Evolution
Chatterjee, K. (1996) · Circulation · doi:10.1161/01.cir.94.11.2689 · Cited by 35
Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction
Jansson, J.-H., Boman, K., & Nilsson, T. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315549 · Cited by 35
Drugs, Heart Failure and Quality of Life
Doba, N., Tomiyama, H., & Nakayama, T. (1999) · Drugs & Aging · doi:10.2165/00002512-199914030-00001 · Cited by 35
Cell death in the failing heart: Role of an unnatural growth response to overload-Cell death in the failing heart
Katz, A. M. (1995) · Clinical Cardiology · doi:10.1002/clc.4960181607 · Cited by 35
Heart Failure: Management of Patients With Left‐Ventricular Systolic Dysfunction
(1996) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.1996.tb00636.x · Cited by 35
There is no scientific rationale for race-based research.
Hoover, E. L. (2007) · PubMed Central · Cited by 34
Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012
McMurray, J. J. V., Adamopoulos, S. N., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G. S., Fonseca, C., Sánchez, M. Á. G., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.08.003 · Cited by 36
Medical Therapy for Functional Mitral Regurgitation
Milwidsky, A., Mathai, S. V., Topilsky, Y., & Jorde, U. P. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009689 · Cited by 34
Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases
BORER, J. S. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/sum037 · Cited by 34
Comparing classifications of death in the Mode Selection Trial: Agreement and disagreement among site investigators and a clinical events committee
Petersen, J. L., Haque, G., Hellkamp, A. S., Flaker, G. C., Estes, N. A. M., Marchlinski, F. E., McAnulty, J. H., Greenspon, A. J., Marinchak, R. A., Lee, K. L., et al. (2006) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.02.002 · Cited by 34
Diabetic cardiomyopathy
Trost, S. U., & LeWinter, M. M. (2001) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-001-0022-9 · Cited by 34
Characterization of the Pharmacokinetic and Pharmacodynamic Properties of the Angiotensin-Converting Enzyme Inhibitor, Enalapril, in Horses
Gardner, S. Y., Atkins, C. E., Sams, R. A., Schwabenton, A. B., & Papich, M. G. (2004) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2004.tb00166.x · Cited by 34
Improving Outcomes in Congestive Heart Failure: Val-HeFT
Cohn, J. N. (1999) · Cardiology · doi:10.1159/000047284 · Cited by 34
Self-citation
Management of heart failure in primary care after implementation of the National Service Framework for Coronary Heart Disease: a cross-sectional study
Majeed, A., Williams, J., de Lusignan, S., & Chan, T. (2004) · Public Health · doi:10.1016/j.puhe.2004.06.006 · Cited by 34
Possible Heart Failure Exacerbation Associated with Rosiglitazone: Case Report and Literature Review
Page, R. L., II, Gozansky, W. S., & Ruscin, J. M. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.7.945.32721 · Cited by 34
Percent achieved of predicted peak exercise oxygen uptake and kinetics of recovery of oxygen uptake after exercise for risk stratification in chronic heart failure
Scrutinio, D., Passantino, A., Lagioia, R., Napoli, F., Ricci, A., & RIZZON, P. (1998) · International Journal of Cardiology · doi:10.1016/s0167-5273(98)00019-9 · Cited by 34
Non-invasive prognostic factors in chronic heart failure. One-year survival of 300 patients with a diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy
Špinar, J., Vítovec, J., Špác, J., Blaha, M., Špinarová, L., & Toman, J. (1996) · International Journal of Cardiology · doi:10.1016/0167-5273(96)02740-4 · Cited by 34
Ventricular arrhythmias in heart failure
Gorgels, A. P. M., Vos, M. A., Smeets, J. L. R. M., & Wellens, H. J. J. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91356-9 · Cited by 34
Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction
Schädlich, P. K., Huppertz, E., & Brecht, J. G. (1998) · PharmacoEconomics · doi:10.2165/00019053-199814060-00006 · Cited by 34
Neurohumoral Aspects of Heart Failure
Benedict, C. R. (1994) · Cardiology Clinics · doi:10.1016/s0733-8651(18)30122-x · Cited by 34
Prognosis in Congestive Heart Failure
DOMANSKI, M. J., Garg, R., & Yusuf, S. (1994) · Springer eBooks · doi:10.1007/978-1-4613-8315-4_33 · Cited by 34
Etiology and characteristics of congestive heart failure in blacks
Mathew, J., Davidson, S., Narra, L., Hafeez, T., & Garg, R. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00635-2 · Cited by 34
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction
Sander, G. E., McKinnie, J. J., Greenberg, S. S., & Giles, T. D. (1999) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.1999.0410265 · Cited by 34
Dynamic cardiomyoplasty acutely impairs left ventricular diastolic function
Corin, W. J., George, D. T., Sink, J. D., & Santamore, W. P. (1992) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)33898-x · Cited by 34
The aspirin–angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not∗∗Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Hall, D. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00637-9 · Cited by 34
Prevalence and characteristics of diabetic patients in a chronic heart failure population
Kistorp, C., Galatius, S., Gustafsson, F., Faber, J., Corell, P., & Hildebrandt, P. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.10.024 · Cited by 33
Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction
Sullivan, L. T., Randolph, T. C., Merrill, P., Jackson, L. R., Egwim, C., Starks, M. A., & Thomas, K. L. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.10.025 · Cited by 35
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
Dewan, P., Docherty, K. F., & McMurray, J. J. V. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2019.0136 · Cited by 33
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 33
Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy
Schwebe, M., Ameling, S., Hammer, E., Monzel, J. V., Bonitz, K., Budde, S., Schult, K., Oswald, S., Scheuch, E., Grube, M., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.01.014 · Cited by 33
Nitrate Therapy for Heart Failure
Gupta, D., Georgiopoulou, V. V., Kalogeropoulos, A. P., Marti, C. N., Yancy, C. W., Gheorghiade, M., Fonarow, G. C., Konstam, M. A., & Butler, J. (2013) · JACC Heart Failure · doi:10.1016/j.jchf.2013.03.003 · Cited by 33
Congestive Heart Failure
Poppas, A., & Rounds, S. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.1.2102075 · Cited by 33
Evaluating the Use of Angiotensin‐Converting Enzyme Inhibitors For Older Nursing Home Residents with Chronic Heart Failure
Forman, D. E., Cbander, R. B., Lapane, K. L., Shah, P., & Stoukides, J. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb01541.x · Cited by 33
Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure
Evans, M. A., Burnett, J. C. J., & Redfield, M. M. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00006-p · Cited by 33
Pharmacologic Blockade of the Renin‐Angiotensin System: Vascular Benefits Beyond Commonly Understood Pharmacologic Actions
Tsikouris, J. P., & Cox, C. D. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.10.1141.32763 · Cited by 33
Arrhythmias and Sudden Death in Heart Failure
Stevenson, W. G., & Sweeney, M. O. (1997) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.61.727 · Cited by 33
Early reduction of neurohumoral factors plays a key role in mediating the efficacy of β-blocker therapy for congestive heart failure
Yoshikawa, T., Handa, S., Anzai, T., Nishimura, H., Baba, A., Akaishi, M., Mitamura, H., & Ogawa, S. (1996) · American Heart Journal · doi:10.1016/s0002-8703(96)90362-2 · Cited by 33
Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction.
Cleland, J. G. F., Shah, D., Krikler, S. J., Dritsas, A., Nihoyannopoulos, P., Frost, G. S., & Oakley, C. M. (1993) · Heart · doi:10.1136/hrt.69.6.512 · Cited by 33
Underutilization of Evidence-Based Therapy in Heart Failure
DEEDWANIA, P. C. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.21.2409 · Cited by 33
Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review
Farag, M., Mabote, T., Shoaib, A., Zhang, J., Nabhan, A. F., Clark, A. L., & Cleland, J. G. F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.160 · Cited by 32
Heart Failure in Diabetes and Related Conditions
Kamalesh, M. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.07.007 · Cited by 32
Sudden Cardiac Death and the Role of Medical Therapy
Arshad, A., Mandava, A., Kamath, G. S., & Musat, D. L. (2008) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2007.12.003 · Cited by 32
Comparison of the Effects of Efonidipine and Amlodipine on Aldosterone in Patients with Hypertension
Tanaka, T., Tsutamoto, T., SAKAI, H., Fujii, M., Yamamoto, T., & Horie, M. (2007) · Hypertension Research · doi:10.1291/hypres.30.691 · Cited by 32
Electrical Modulation of Cardiac Contractility: Clinical Aspects in Congestive Heart Failure
Pappone, C., Vicedomini, G., Salvati, A., Meloni, C., Haddad, W., Aviv, R., Mika, Y., Darvish, N., Kimchy, Y., Shemer, I., et al. (2001) · Heart Failure Reviews · doi:10.1023/a:1009807309006 · Cited by 32
Neurohumoral activations in congestive heart failure: Correlations with cardiac function, heart rate variability, and baroreceptor sensitivity
Yoshikawa, T., Baba, A., Akaishi, M., Mitamura, H., Ogawa, S., Suzuki, M., Negishi, K., Takahashi, T., & Murayama, A. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70220-6 · Cited by 32
Predictors of mortality in patients with sustained ventricular tachycardias or ventricular fibrillation and depressed left ventricular function: Importance of β-blockade
Szabó, B. M., Crijns, H. J. G. M., Wiesfeld, A. C. P., van Veldhuisen, D. J., Hillege, H. L., & Lie, K. I. (1995) · American Heart Journal · doi:10.1016/0002-8703(95)90441-7 · Cited by 32
Captopril and spironolactone therapy for refractory congestive heart failure
Dahlström, U., & Karlsson, E. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90242-5 · Cited by 32
Combination of Isosorbide Dinitrate and Hydralazine in Blacks With Heart Failure
Virk, I. S., & Ip, R. (2005) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2005.04167.x · Cited by 31
Gender Differences in Ischemic Cardiomyopathy
Divoky, L., Maran, A., & Ramu, B. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0750-x · Cited by 31
PDE3 inhibition in dilated cardiomyopathy
Movsesian, M. A., Wever‐Pinzon, O., & Vandeput, F. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.09.001 · Cited by 31
Different angiotensin‐converting enzyme inhibitors have similar clinical efficacy after myocardial infarction
Hansen, M. L., Gislason, G., Køber, L., Schramm, T. K., Folke, F., Buch, P., Abildstrom, S. Z., Madsen, M., Rasmussen, S., & Torp-Pedersen, C. T. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02991.x · Cited by 31
Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure
Dickstein, K., Timmermans, P. B. M. W. M., & Segal, R. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.11.1897 · Cited by 31
ACE-Inhibition and Angiotensin II Receptor Blockers in Chronic Heart Failure: Pathophysiological Consideration of the Unresolved Battle
Šimko, F., Simko, J., & Fabryova, M. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026215712983 · Cited by 31
Mibefradil, a Pharmacologically Distinct Calcium Antagonist
Ernst, M. E., & Kelly, M. W. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03110.x · Cited by 31
Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease
Simonsen, U. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900846 · Cited by 31
Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversión de la angiotensina en la enfermedad cardiovascular
Lopez-Sendon, J. L., Swedberg, K., McMurray, J. J. V., Tamargo, J. L., Maggioni, A. P., Dargie, H., Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P. P., et al. (2004) · Revista Española de Cardiología · doi:10.1016/s0300-8932(04)77264-4 · Cited by 31
Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure
Stehlik, J., & Movsesian, M. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.733 · Cited by 31
Heart Failure in Women
Halm, M. A., & Penque, S. (2000) · Progress in Cardiovascular Nursing · doi:10.1111/j.0889-7204.2000.080399.x · Cited by 31
Left Ventricular and Biventricular Pacing in Congestive Heart Failure
Gerber, T. C., Nishimura, R. A., Holmes, D. R., Lloyd, M. A., Zehr, K. J., Tajik, A. J., & Hayes, D. L. (2001) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)63225-4 · Cited by 31
Endothelial Dysfunction: Implications for Therapy of Cardiovascular Diseases
Bell, D., Johns, T. E., & Lopez, L. M. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17084 · Cited by 31
Acute Myocardial Infarction
Spratt, K. A., Huehns, T. Y., & Wilensky, R. L. (1998) · Developments in cardiovascular medicine · doi:10.1007/978-1-4615-5715-9_5 · Cited by 31
Mechanical cardiac support 2000: current applications and future trial design
Stevenson, L. (2001) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(00)01099-8 · Cited by 31
Inotropic therapy for the failing myocardium
Shipley, J. B., & Hess, M. L. (1995) · Clinical Cardiology · doi:10.1002/clc.4960181106 · Cited by 31
Angiotensin-converting enzyme inhibition in congestive heart failure: Benefit and perspective
Pfeffer, M. A. (1993) · American Heart Journal · doi:10.1016/0002-8703(93)90931-x · Cited by 31
β‐Blocker Use in Systolic Heart Failure and Dilated Cardiomyopathy
Hash, T. W., & Prisant, L. M. (1997) · The Journal of Clinical Pharmacology · doi:10.1177/009127009703700103 · Cited by 31
Prescribing BiDil
Haga, S. B., & Ginsburg, G. S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.017 · Cited by 30
Cardiovascular therapeutics: A new potential for anxiety treatment?
Repova, K., Aziriova, S., Krajcirovicova, K., & Šimko, F. (2022) · Medicinal Research Reviews · doi:10.1002/med.21875 · Cited by 30
Mesoporous Poly(Ionic Liquid) Solid Acid for Sequential Dehydration of Sorbitol to Isosorbide
Yuan, D., Xiao, F., Zhao, N., Deng, C., Huang, X. M., Zhang, H., Yang, Q., & Qiao, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.141780 · Cited by 30
A Perspective on Re-Evaluating Digoxin's Role in the Current Management of Patients with Chronic Systolic Heart Failure: Targeting Serum Concentration to Reduce Hospitalization and Improve Safety Profile
Adams, K. F., Ghali, J. K., Patterson, J. H., Stough, W. G., Butler, J., Bauman, J. L., Ventura, H. O., Sabbah, H. N., Mackowiak, J. I., & van Veldhuisen, D. J. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.64 · Cited by 30
Effects of Nitrates and Hydralazine in Heart Failure: Clinical Evidence Before the African American Heart Failure Trial
Elkayam, U., & Bitar, F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.031 · Cited by 30
A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination
Cheng, J. W. M. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.05.007 · Cited by 30
Cardiac rehabilitation and survival in patients with left ventricular systolic dysfunction
Whellan, D. J., Shaw, L. K., Bart, B. A., Kraus, W. E., Califf, R. M., & O’Connor, C. M. (2001) · American Heart Journal · doi:10.1067/mhj.2001.115785 · Cited by 30
Purification and assay methods for angiotensin-converting enzyme
Meng, Q. C., & Oparil, S. (1996) · Journal of Chromatography A · doi:10.1016/0021-9673(96)00372-x · Cited by 30
Relationship between the increase in Ca2+ transient and contractile force induced by angiotensin II in aequorin-loaded rabbit ventricular myocardium
Watanabe, A. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00287-3 · Cited by 30
Simple Clinical Criteria to Determine the Prognosis of Heart Failure
Heywood, J. T., Elatre, W. A., Pai, R. G., Fabbri, S. C., & Huiskes, B. (2005) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840501000305 · Cited by 30
Left ventricular remodelling and dysfunction
Willenheimer, R. B. (2000) · International Journal of Cardiology · doi:10.1016/s0167-5273(99)00182-5 · Cited by 30
Current Status of Phosphodiesterase Inhibitors in the Treatment of Congestive Heart Failure
Fischer, T. A., Erbel, R. M., & Treese, N. (1992) · Drugs · doi:10.2165/00003495-199244060-00003 · Cited by 30
Heart Failure With Better Ejection Fraction
Stevenson, L. W. (2014) · Circulation · doi:10.1161/circulationaha.114.010194 · Cited by 30
Age and the Cardiovascular System
Winker, M. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304293281715 · Cited by 30
Effect of Piboserod, a 5-HT4 Serotonin Receptor Antagonist, on Left Ventricular Function in Patients with Symptomatic Heart Failure
KJEKSHUS, J. K., Torp-Pedersen, C. T., Gullestad, L. L., Køber, L., Edvardsen, T., Olsen, I. C., Sjaastad, I., Qvigstad, E., Skomedal, T., Osnes, J., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp087 · Cited by 29
New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) III: Endogenous Inhibition of Angiotensin Converting Enzyme (ACE) Provides Protection against Cardiovascular Diseases
Fagyas, M., Katalin, Ú., Siket, I. M., Daragó, A., Boczán, J., Bányai, E., Edes, I. F., Papp, Z., & Tóth, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093719 · Cited by 29
New medications for heart failure
Gordin, J. S., & Fonarow, G. C. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.02.008 · Cited by 29
Defining the molecular signatures of human right heart failure
Williams, J. L., Cavus, O., Loccoh, E. C., Adelman, S. A., Daugherty, J. C., Smith, S. A., Canan, B. D., Janssen, P. M. L., Koenig, S. N., Kline, C. F., et al. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.01.021 · Cited by 29
Pharmacological treatment of chronic heart failure
Adorisio, R., Luca, L. D., Rossi, J. S., & Gheorghiade, M. (2006) · Heart Failure Reviews · doi:10.1007/s10741-006-9482-z · Cited by 29
Using the Emergency Department Clinical Decision Unit for Acute Decompensated Heart Failure
Peacock, W. F. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2005.08.014 · Cited by 29
The African-American Heart Failure Trial: background, rationale and significance.
Taylor, A. L., Cohn, J. N., Worcel, M., & Franciosa, J. A. (2002) · PubMed Central · Cited by 29
Self-citation
Comparison of echocardiography and radionuclide angiography as predictors of mortality in patients with left ventricular dysfunction (studies of left ventricular dysfunction)
Rashid, H., Exner, D. V., MIRSKY, I., Cooper, H. A., Waclawiw, M. A., & DOMANSKI, M. J. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00280-5 · Cited by 29
Coronary artery disease and prevention of heart failure
Klein, L., & Gheorghiade, M. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.03.002 · Cited by 31
Intensive Session: New Approaches to Medical Issues in Long-Term Care
Messinger‐Rapport, B. J., Morley, J. E., Thomas, D. R., & Gammack, J. K. (2007) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2007.07.002 · Cited by 29
Improving clinical outcomes with drug treatment in heart failure: what have trials taught?
Konstam, M. A. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03374-x · Cited by 29
Improvement of Vagal Tone by ACE Inhibition: A Mechanism of Cardioprotection in Patients with Mild-to-Moderate Heart Failure
Osterziel, K. J., & Dietz, R. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199600002-00006 · Cited by 29
The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure
Jamali, A. H., Tang, W. H. W., Khot, U. N., & Fowler, M. B. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.5.667 · Cited by 29

Authors: Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., Bhat, G., Goldman, S., Fletcher, R. D., Doherty, J., Hughes, C. V., Carson, P., Cintron, G., Shabetai, R., & Haakenson, C.
Affiliations: University of Minnesota (US)
ORCID: Cohn, Jay N.
Johnson, Gary
Bhat, Geetha
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1991-08
Volume: 325
Issue: 5
Pages: 303-310
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199108013250502
OpenAlex: W2046383587
Cited by: 2,833
References: 19
Citations by year: 2026: 14 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 27 · 2020: 46 · 2019: 39 · 2018: 51 · 2017: 56 · 2016: 69 · 2015: 59 · 2014: 54 · 2013: 61 · 2012: 56
FWCI: 124.25
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: enalapril, hydralazine, isosorbide dinitrate, chronic congestive heart failure, vasodilator therapy, mortality, sudden death, exercise oxygen consumption, left ventricular ejection fraction, ACE inhibitors, combination therapy, digoxin, diuretics, NYHA functional class
MeSH terms: Adolescent, Adult, Aged, Chronic Disease, Death, Sudden, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Enalapril, Physical Exertion, Heart Failure, Hospitalization, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Norepinephrine, Oxygen Consumption, Patient Compliance, Stroke Volume, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks